Schirmer, Markus Anton

[["dc.bibliographiccitation.firstpage","3384"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Patzer, Christoph"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Possiel, Jacqueline"],["dc.contributor.author","Pilavakis, Yiannis"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.date.accessioned","2021-09-01T06:43:07Z"],["dc.date.available","2021-09-01T06:43:07Z"],["dc.date.issued","2021"],["dc.description.abstract","Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, n = 52) and younger patients (n = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved."],["dc.description.abstract","Locally advanced head and neck squamous cell carcinomas (HNSCC) are often managed with surgery followed by postoperative radiochemotherapy (RCT). With the general increase in life expectancy, the proportion of elderly patients with HNSCC is expected to grow rapidly. Until now, a deeper understanding of specific management strategies for these patients in clinical routine was lacking. In the present study, we compared elderly patients (≥70 years, n = 52) and younger patients (n = 245) treated with postoperative RCT for HNSCC at our tertiary cancer center. All patients were irradiated with modern radiotherapy techniques (IMRT/VMAT). Patients ≥70 years of age had more comorbidities. Additionally, elderly patients less frequently received concomitant systemic treatment. The rates of mucositis and dermatitis were lower in patients ≥70 years. Elderly patients had significantly worse overall and progression-free survival. Locoregional and distant control were comparable in elderly and younger patients. In conclusion, postoperative RCT is a safe and effective treatment option in patients ≥70 years. In light of comorbidities and poor overall survival rates, benefits and harms of radiotherapy and concomitant systemic treatment should be weighed carefully. When exclusively applying up-to-date radiotherapy techniques with, at the same time, careful use of concomitant systemic therapy, favorable acute toxicity profiles are achieved."],["dc.identifier.doi","10.3390/cancers13143384"],["dc.identifier.pii","cancers13143384"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/89222"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-455"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Postoperative Radiochemotherapy Using Modern Radiotherapy Techniques in Elderly Patients with Head and Neck Squamous Cell Carcinoma: The Challenge of Weighing Up Benefits and Harms of Treatment Modalities in Clinical Practice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2805"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Riebeling, Theresa"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Hubert, Laura"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.date.accessioned","2021-07-05T15:00:42Z"],["dc.date.available","2021-07-05T15:00:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer."],["dc.description.abstract","Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.3390/cancers13112805"],["dc.identifier.pii","cancers13112805"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87886"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2533"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Possiel, Jacqueline"],["dc.contributor.author","Ammon, Hanne Elisabeth"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Samel, Stephan"],["dc.contributor.author","Mügge, Michael"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Leu, Martin"],["dc.date.accessioned","2021-07-05T15:00:42Z"],["dc.date.available","2021-07-05T15:00:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Intensity-modulated radiotherapy (IMRT) is the standard of care in chemoradiotherapy (CRT) for anal cancer. Until now, only a limited number of studies have analyzed the results with VMAT (volumetric modulated arc therapy). We conducted a retrospective study on patients treated at our institution. Patients and Methods: We included patients who received curative CRT for anal cancer. We compared VMAT-treated and 3DCRT (3D conformal radiotherapy)-treated patients. We analyzed toxicities (acute: CTCAE criteria; late: LENT/SOMA criteria), treatment compliance, overall survival, cancer-specific survival (CSS), distant control (DC), and locoregional control. Results: A total of 149 patients (3DCRT: n = 87, VMAT: n = 62) were included. The median follow-up was longer in 3DCRT-treated patients (3DCRT: 61.3 months; VMAT: 39.1 months; p < 0.05). VMAT-treated patients had more G3 tumors (3DCRT: 12/87 (13.8%); VMAT: 18/62 (29.0%), p < 0.001). VMAT reduced acute toxicities ≥grade 3 (3DCRT: n = 48/87 (55.2%); VMAT: n = 11/62 (17.7%), p < 0.001). VMAT improved treatment compliance (less interruptions/delays) (3DCRT: 37/87, 42.5%; VMAT: 4/62, 6.5%; p < 0.001), provided a shorter median overall treatment time (3DCRT: 41 days; VMAT: 38 days; p = 0.02), and gave a higher median absolute 5-fluorouracil dose (3DCRT: 13,700 mg; VMAT: 14,400 mg; p = 0.001). Finally, we found improved CSS (p = 0.02; 3DCRT: 81.9% at 3 years; VMAT: 94.1% at 3 years) and DC (p = 0.01; 3DCRT: 89.4% at 3 years; VMAT: 100.0% at 3 years) with VMAT. Summary: Our study is the first to demonstrate improved treatment compliance and outcomes with VMAT for anal cancer. Previous studies have indicated that organs at risk sparing might be more improved with the use of VMAT vs. with conventional IMRT. Future studies should address whether these advantages lead to a further reduction in CRT-associated morbidity."],["dc.description.abstract","Background: Intensity-modulated radiotherapy (IMRT) is the standard of care in chemoradiotherapy (CRT) for anal cancer. Until now, only a limited number of studies have analyzed the results with VMAT (volumetric modulated arc therapy). We conducted a retrospective study on patients treated at our institution. Patients and Methods: We included patients who received curative CRT for anal cancer. We compared VMAT-treated and 3DCRT (3D conformal radiotherapy)-treated patients. We analyzed toxicities (acute: CTCAE criteria; late: LENT/SOMA criteria), treatment compliance, overall survival, cancer-specific survival (CSS), distant control (DC), and locoregional control. Results: A total of 149 patients (3DCRT: n = 87, VMAT: n = 62) were included. The median follow-up was longer in 3DCRT-treated patients (3DCRT: 61.3 months; VMAT: 39.1 months; p < 0.05). VMAT-treated patients had more G3 tumors (3DCRT: 12/87 (13.8%); VMAT: 18/62 (29.0%), p < 0.001). VMAT reduced acute toxicities ≥grade 3 (3DCRT: n = 48/87 (55.2%); VMAT: n = 11/62 (17.7%), p < 0.001). VMAT improved treatment compliance (less interruptions/delays) (3DCRT: 37/87, 42.5%; VMAT: 4/62, 6.5%; p < 0.001), provided a shorter median overall treatment time (3DCRT: 41 days; VMAT: 38 days; p = 0.02), and gave a higher median absolute 5-fluorouracil dose (3DCRT: 13,700 mg; VMAT: 14,400 mg; p = 0.001). Finally, we found improved CSS (p = 0.02; 3DCRT: 81.9% at 3 years; VMAT: 94.1% at 3 years) and DC (p = 0.01; 3DCRT: 89.4% at 3 years; VMAT: 100.0% at 3 years) with VMAT. Summary: Our study is the first to demonstrate improved treatment compliance and outcomes with VMAT for anal cancer. Previous studies have indicated that organs at risk sparing might be more improved with the use of VMAT vs. with conventional IMRT. Future studies should address whether these advantages lead to a further reduction in CRT-associated morbidity."],["dc.identifier.doi","10.3390/cancers13112533"],["dc.identifier.pii","cancers13112533"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87885"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Kitz, J."],["dc.contributor.author","Pilavakis, Y."],["dc.contributor.author","Hakroush, S."],["dc.contributor.author","Wolff, H. A."],["dc.contributor.author","Canis, M."],["dc.contributor.author","Rieken, S."],["dc.contributor.author","Schirmer, M. A."],["dc.date.accessioned","2021-06-01T09:41:42Z"],["dc.date.available","2021-06-01T09:41:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract Treatment of locally advanced, unresectable head and neck squamous cell carcinoma (HNSCC) often yields only modest results with radiochemotherapy (RCT) as standard of care. Prognostic features related to outcome upon RCT might be highly valuable to improve treatment. Monocarboxylate transporters-1 and -4 (MCT1/MCT4) were evaluated as potential biomarkers. A cohort of HNSCC patients without signs for distant metastases was assessed eliciting 82 individuals eligible whereof 90% were diagnosed with locally advanced stage IV. Tumor specimens were stained for MCT1 and MCT4 in the cell membrane by immunohistochemistry. Obtained data were evaluated with respect to overall (OS) and progression-free survival (PFS). Protein expression of MCT1 and MCT4 in cell membrane was detected in 16% and 85% of the tumors, respectively. Expression of both transporters was not statistically different according to the human papilloma virus (HPV) status. Positive staining for MCT1 (n = 13, negative in n = 69) strongly worsened PFS with a hazard ratio (HR) of 3.1 (95%-confidence interval 1.6–5.7, p < 0.001). OS was likewise affected with a HR of 3.8 (2.0–7.3, p < 0.001). Multivariable Cox regression confirmed these findings. We propose MCT1 as a promising biomarker in HNSCC treated by primary RCT."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1038/s41598-021-84019-w"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85012"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","2045-2322"],["dc.relation.orgunit","Klinik für Strahlentherapie und Radioonkologie"],["dc.rights","CC BY 4.0"],["dc.title","Monocarboxylate transporter-1 (MCT1) protein expression in head and neck cancer affects clinical outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1080"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Current Oncology"],["dc.bibliographiccitation.lastpage","1092"],["dc.bibliographiccitation.volume","29"],["dc.contributor.affiliation","Habermann, Felix-Nikolai Oschinka Jegor; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Schmitt, Daniela; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Failing, Thomas; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Fischer, Jann; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Ziegler, David Alexander; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Fischer, Laura Anna; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Alt, Niklas Josua; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Muster, Julian; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Donath, Sandra; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Hille, Andrea; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Schirmer, Markus Anton; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Guhlich, Manuel; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","El Shafie, Rami A.; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Rieken, Stefan; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Leu, Martin; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.affiliation","Dröge, Leif Hendrik; 1Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany; felix.habermann@med.uni-goettingen.de (F.-N.O.J.H.); daniela.schmitt@med.uni-goettingen.de (D.S.); thomas.failing@med.uni-goettingen.de (T.F.); jann.fischer@med.uni-goettingen.de (J.F.); alexander.ziegler@med.uni-goettingen.de (D.A.Z.); laura-anna.fischer@med.uni-goettingen.de (L.A.F.); niklasjosua.alt@stud.uni-goettingen.de (N.J.A.); julian.muster@stud.uni-goettingen.de (J.M.); sandra.donath@med.uni-goettingen.de (S.D.); ahille@med.uni-goettingen.de (A.H.); mschirmer@med.uni-goettingen.de (M.A.S.); manuel.guhlich@med.uni-goettingen.de (M.G.); rami.elshafie@med.uni-goettingen.de (R.A.E.S.); stefan.rieken@med.uni-goettingen.de (S.R.); martin.leu@med.uni-goettingen.de (M.L.)"],["dc.contributor.author","Habermann, Felix-Nikolai Oschinka Jegor"],["dc.contributor.author","Schmitt, Daniela"],["dc.contributor.author","Failing, Thomas"],["dc.contributor.author","Fischer, Jann"],["dc.contributor.author","Ziegler, David Alexander"],["dc.contributor.author","Fischer, Laura Anna"],["dc.contributor.author","Alt, Niklas Josua"],["dc.contributor.author","Muster, Julian"],["dc.contributor.author","Donath, Sandra"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","El Shafie, Rami A."],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Leu, Martin"],["dc.date.accessioned","2022-04-01T10:00:26Z"],["dc.date.available","2022-04-01T10:00:26Z"],["dc.date.issued","2022"],["dc.date.updated","2022-09-03T12:11:44Z"],["dc.description.abstract","The pandemic raised a discussion about the postponement of medical interventions for non-small cell lung cancer (NSCLC). We analyzed the characteristics of pretreatment diagnostic assessment in the pandemic and the influence of diagnostic assessment on outcomes. A total of 96 patients with stereotactic body radiation therapy (SBRT) for NSCLC were included. The number of patients increased from mean 0.9 (2012–2019) to 1.45 per month in the COVID era (p < 0.05). Pandemic-related factors (contact reduction, limited intensive care unit resources) might have influenced clinical decision making towards SBRT. The time from pretreatment assessment (multidisciplinary tumor board decision, bronchoscopy, planning CT) to SBRT was longer during the COVID period (p < 0.05). Reduced services, staff shortage, or appointment management to mitigate infection risks might explain this finding. Overall survival, progression-free survival, locoregional progression-free survival, and distant progression-free survival were superior in patients who received a PET/CT scan prior to SBRT (p < 0.05). This supports that SBRT guidelines advocate the acquisition of a PET/CT scan. A longer time from PET/CT scan/conventional staging to SBRT (<10 vs. ≥10 weeks) was associated with worse locoregional control (p < 0.05). The postponement of diagnostic or therapeutic measures in the pandemic should be discussed cautiously. Patient- and tumor-related features should be evaluated in detail."],["dc.identifier.doi","10.3390/curroncol29020092"],["dc.identifier.pii","curroncol29020092"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105426"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1718-7729"],["dc.rights","CC BY 4.0"],["dc.title","Patterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5585"],["dc.bibliographiccitation.issue","21"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Hubert, Laura"],["dc.contributor.author","Mergler, Caroline Patricia Nadine"],["dc.contributor.author","Rave-Fraenk, Margret"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Schmidberger, Heinz"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.editor","Urbanucci, Alfonso"],["dc.date.accessioned","2022-01-11T14:07:50Z"],["dc.date.available","2022-01-11T14:07:50Z"],["dc.date.issued","2021"],["dc.description.abstract","Genetic variability in transforming growth factor beta pathway (TGFB) was suggested to affect adverse events of radiotherapy. We investigated comprehensive variability in TGFB1 (gene coding for TGFβ1 ligand) and TGFBR1 (TGFβ receptor-1) in relation to radiotoxicity. Prostate cancer patients treated with primary radiotherapy (n = 240) were surveyed for acute and late toxicity. Germline polymorphisms (n = 40) selected to cover the common genetic variability in TGFB1 and TGFBR1 were analyzed in peripheral blood cells. Human lymphoblastoid cell lines (LCLs) were used to evaluate a possible impact of TGFB1 and TGFBR1 genetic polymorphisms to DNA repair capacity following single irradiation with 3 Gy. Upon adjustment for multiplicity testing, rs10512263 in TGFBR1 showed a statistically significant association with acute radiation toxicity. Carriers of the Cytosine (C)-variant allele (n = 35) featured a risk ratio of 2.17 (95%-CI 1.41–3.31) for acute toxicity ≥ °2 compared to Thymine/Thymine (TT)-wild type individuals (n = 205). Reduced DNA repair capacity in the presence of the C-allele of rs10512263 might be a mechanistic explanation as demonstrated in LCLs following irradiation. The risk for late radiotoxicity was increased by carrying at least two risk genotypes at three polymorphic sites, including Leu10Pro in TGFB1. Via comprehensive genotyping of TGFB1 and TGFBR1, promising biomarkers for radiotoxicity in prostate cancer were identified."],["dc.description.abstract","Genetic variability in transforming growth factor beta pathway (TGFB) was suggested to affect adverse events of radiotherapy. We investigated comprehensive variability in TGFB1 (gene coding for TGFβ1 ligand) and TGFBR1 (TGFβ receptor-1) in relation to radiotoxicity. Prostate cancer patients treated with primary radiotherapy (n = 240) were surveyed for acute and late toxicity. Germline polymorphisms (n = 40) selected to cover the common genetic variability in TGFB1 and TGFBR1 were analyzed in peripheral blood cells. Human lymphoblastoid cell lines (LCLs) were used to evaluate a possible impact of TGFB1 and TGFBR1 genetic polymorphisms to DNA repair capacity following single irradiation with 3 Gy. Upon adjustment for multiplicity testing, rs10512263 in TGFBR1 showed a statistically significant association with acute radiation toxicity. Carriers of the Cytosine (C)-variant allele (n = 35) featured a risk ratio of 2.17 (95%-CI 1.41–3.31) for acute toxicity ≥ °2 compared to Thymine/Thymine (TT)-wild type individuals (n = 205). Reduced DNA repair capacity in the presence of the C-allele of rs10512263 might be a mechanistic explanation as demonstrated in LCLs following irradiation. The risk for late radiotoxicity was increased by carrying at least two risk genotypes at three polymorphic sites, including Leu10Pro in TGFB1. Via comprehensive genotyping of TGFB1 and TGFBR1, promising biomarkers for radiotoxicity in prostate cancer were identified."],["dc.identifier.doi","10.3390/cancers13215585"],["dc.identifier.pii","cancers13215585"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/97876"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-507"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Identification of Risk Loci for Radiotoxicity in Prostate Cancer by Comprehensive Genotyping of TGFB1 and TGFBR1"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Baumeister, Philipp"],["dc.contributor.author","Hollmann, Alessandra"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Afthonidou, Artemis"],["dc.contributor.author","Simon, Florian"],["dc.contributor.author","Shakhtour, Julius"],["dc.contributor.author","Mack, Brigitte"],["dc.contributor.author","Kranz, Gisela"],["dc.contributor.author","Libl, Darko"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Schirmer, Markus A."],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Belka, Claus"],["dc.contributor.author","Zitzelsberger, Horst"],["dc.contributor.author","Ganswindt, Ute"],["dc.contributor.author","Hess, Julia"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Unger, Kristian"],["dc.contributor.author","Gires, Olivier"],["dc.date.accessioned","2020-12-10T18:10:12Z"],["dc.date.available","2020-12-10T18:10:12Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1038/s41598-018-32178-8"],["dc.identifier.eissn","2045-2322"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15447"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73883"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","High Expression of EpCAM and Sox2 is a Positive Prognosticator of Clinical Outcome for Head and Neck Carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3613"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Possiel, Jacqueline"],["dc.contributor.author","Schirmer, Markus A."],["dc.contributor.author","Hille, Andrea"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.date.accessioned","2021-04-14T08:27:10Z"],["dc.date.available","2021-04-14T08:27:10Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/cancers12123613"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82194"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Evaluation of Prognosticators and Treatment-Related Side Effects in Patients Irradiated Postoperatively for Endometrial Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1834"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Karras, Philipp Johannes"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Ghadimi, Michael"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Leu, Martin"],["dc.date.accessioned","2021-06-01T09:42:31Z"],["dc.date.available","2021-06-01T09:42:31Z"],["dc.date.issued","2021"],["dc.description.abstract","We retrospectively studied outcomes in patients treated with preoperative radiochemotherapy and surgery for esophageal squamous cell cancer. We put special focus on the comparison of patients treated with 5-fluorouracil/cisplatin (‘Walsh’) or carboplatin/paclitaxel (‘CROSS’). We compared characteristics between patients treated according to ‘Walsh’ vs. ‘CROSS’. Cox regression was performed to test for an association of parameters with outcomes. Study eligibility was met by 90 patients. First, the higher age and more comorbidities of the ‘CROSS’ patients, along with a shorter intensive care/intermediate care stay, might reflect an improvement in supportive and surgical/perioperative procedures over the periods. Second, the ‘CROSS’ patients experienced more hematologic toxicity and were less likely to complete chemotherapy as per protocol. This indicates that efforts should be taken to guide patients through a toxic treatment regimen by supportive measures. Third, the negative prognostic impact of radiochemotherapy-related toxicities (i.e., dysphagia and hematologic toxicities) and the duration of the intensive care/intermediate care unit stay underlines that further optimization of treatment procedures remains an important goal. We found no differences in tumor downstaging and survival between treatment regimen. Toxicity profiles could be improved by tailoring the regimen to individual patients (e.g., careful use of the taxane-based regimen in elderly patients)."],["dc.identifier.doi","10.3390/cancers13081834"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85276"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Preoperative Radiochemotherapy in Esophageal Squamous Cell Cancer with 5-Fluorouracil/Cisplatin or Carboplatin/Paclitaxel: Treatment Practice over a 20-Year Period and Implications for the Individual Treatment Modalities"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]